The HemOnc Pulse Live at ASH 2022: Elias Jabbour, MD, on Immunotherapy Advances in ALL
By Chadi Nabhan, MD, MBA, FACP, Elias Jabbour, MD - Last Updated: December 13, 2022Elias Jabbour, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about advances in frontline treatment for acute lymphoblastic leukemia (ALL), immunotherapy, using minimal residual disease data to tailor therapy, strategies for treating patients with relapsed disease, and more, during the 2022 American Society of Hematology Annual Meeting.
Post Tags:ASH22
Advertisement
Related Posts
No relapses occurred in patients who achieved early MRD negativity per the next-generation sequencing MRD assay.
Brexucabtagene autoleucel led to “high rates of durable response” in adults with relapsed/refractory B-cell ALL.
Ponatinib was more effective than imatinib when given with reduced-intensity chemotherapy in newly diagnosed Ph+ ALL.
All patients had a complete response after the first infusion, while 67% had a complete response after the second infusion.
The efficacy of CNS prophylaxis with intrathecal chemotherapy in Ph+ ALL depends upon how many times it is given.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726